Weybosset Research & Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,505
| Closed | -$267K | – | 35 |
|
|
2024
Q4 | $267K | Hold |
1,505
| – | – | 0.09% | 39 |
|
|
2024
Q3 | $297K | Hold |
1,505
| – | – | 0.1% | 36 |
|
|
2024
Q2 | $258K | Buy |
1,505
+50
| +3% | +$8.28K | 0.1% | 36 |
|
|
2024
Q1 | $673 | Sell |
1,455
-250
| -15% | -$43.1K | 0.23% | 27 |
|
|
2023
Q4 | $264K | Buy |
1,705
+100
| +6% | +$14.6K | 0.09% | 36 |
|
|
2023
Q3 | $239K | Hold |
1,605
| – | – | 0.1% | 35 |
|
|
2023
Q2 | $216K | Sell |
1,605
-1,645
| -51% | -$241K | 0.08% | 37 |
|
|
2023
Q1 | $518K | Sell |
3,250
-200
| -6% | -$30.6K | 0.2% | 28 |
|
|
2022
Q4 | $558K | Buy |
3,450
+200
| +6% | +$30.7K | 0.22% | 27 |
|
|
2022
Q3 | $436K | Buy |
3,250
+500
| +18% | +$71.7K | 0.19% | 28 |
|
|
2022
Q2 | $201K | Buy |
+2,750
| New | +$420K | 0.1% | 46 |
|
|
2021
Q4 | – | Sell |
-2,000
| Closed | -$216K | – | 51 |
|
|
2021
Q3 | $216K | Sell |
2,000
-1,300
| -39% | -$149K | 0.09% | 49 |
|
|
2021
Q2 | $372K | Buy |
3,300
+200
| +6% | +$22.5K | 0.15% | 37 |
|
|
2021
Q1 | $335K | Hold |
3,100
| – | – | 0.14% | 42 |
|
|
2020
Q4 | $332K | Sell |
3,100
-300
| -9% | -$28.8K | 0.15% | 38 |
|
|
2020
Q3 | $298K | Sell |
3,400
-1,050
| -24% | -$98.9K | 0.16% | 42 |
|
|
2020
Q2 | $437K | Hold |
4,450
| – | – | 0.26% | 33 |
|
|
2020
Q1 | $321K | Hold |
4,450
| – | – | 0.23% | 37 |
|
|
2019
Q4 | $394K | Buy |
+4,450
| New | +$369K | 0.21% | 44 |
|
|
2019
Q3 | – | Sell |
-4,450
| Closed | -$324K | – | 44 |
|
|
2019
Q2 | $324K | Hold |
4,450
| – | – | 0.19% | 46 |
|
|
2019
Q1 | $3.59M | Sell |
4,450
-250
| -5% | -$20.5K | 2.11% | 20 |
|
|
2018
Q4 | $433K | Buy |
+4,700
| New | +$413K | 0.3% | 33 |
|
|
2018
Q3 | – | Sell |
-3,675
| Closed | -$340K | – | 56 |
|
|
2018
Q2 | $340K | Hold |
3,675
| – | – | 0.21% | 44 |
|
|
2018
Q1 | $348K | Sell |
3,675
-450
| -11% | -$49.4K | 0.21% | 43 |
|
|
2017
Q4 | $399K | Sell |
4,125
-475
| -10% | -$44.8K | 0.24% | 42 |
|
|
2017
Q3 | $409K | Sell |
4,600
-100
| -2% | -$7.61K | 0.27% | 38 |
|
|
2017
Q2 | $341K | Buy |
4,700
+200
| +4% | +$13.4K | 0.22% | 46 |
|
|
2017
Q1 | $293K | Buy |
4,500
+800
| +22% | +$50.3K | 0.2% | 48 |
|
|
2016
Q4 | $232K | Hold |
3,700
| – | – | 0.16% | 51 |
|
|
2016
Q3 | $233K | Hold |
3,700
| – | – | 0.17% | 52 |
|
|
2016
Q2 | $229K | Hold |
3,700
| – | – | 0.17% | 51 |
|
|
2016
Q1 | $211K | Buy |
+3,700
| New | +$206K | 0.18% | 51 |
|
|
2015
Q3 | – | Sell |
-3,475
| Closed | -$233K | – | 54 |
|
|
2015
Q2 | $233K | Hold |
3,475
| – | – | 0.15% | 48 |
|
|
2015
Q1 | $203K | Hold |
3,475
| – | – | 0.13% | 52 |
|
|
2014
Q4 | $227K | Hold |
3,475
| – | – | 0.14% | 51 |
|
|
2014
Q3 | $201K | Sell |
3,475
-1,250
| -26% | -$69.4K | 0.14% | 51 |
|
|
2014
Q2 | $267K | Hold |
4,725
| – | – | 0.17% | 45 |
|
|
2014
Q1 | $243K | Sell |
4,725
-100
| -2% | -$5.05K | 0.16% | 46 |
|
|
2013
Q4 | $255K | Buy |
+4,825
| New | +$237K | 0.17% | 43 |
|
Other funds holding ABBV
Weybosset Research & Management's ABBV Position: Q1 2025 in Review
Weybosset Research & Management sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 1,505 shares — an estimated $267K sold.
Weybosset Research & Management first reported a position in ABBV in Q4 2013 and held it in 39 quarters. The position peaked at $3.59M in Q1 2019. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.
- Weybosset Research & Management reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
- Weybosset Research & Management sold 1,505 AbbVie shares in Q1 2025, an estimated $267K.
- Weybosset Research & Management first reported a position in AbbVie in Q4 2013 and held it in 39 quarters.
- Weybosset Research & Management's AbbVie position peaked at $3.59M in Q1 2019.
- 3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.
Based on Weybosset Research & Management's 13F filing for Q1 2025, filed 9 Apr 2025.